Skip to main content
    T

    Tempest Therapeutics Inc (TPST)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.34
    -0.04 (-10.50%)

    Market Cap: $7.64M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Tempest Therapeutics Inc (TPST) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Tempest Therapeutics are Marker Therapeutics (MRKR), GT Biopharma (GTBP) and Intensity Therapeutics, Inc. Common stock (INTS). By market cap, Tempest Therapeutics ranks 9th of the 13 companies on this page; Marker Therapeutics (MRKR) is the largest at $14.51M.

    Peer Comparison

    TPST's ROIC of -783.6% is below the peer median of -72.3%, and its revenue growth of 0.0% is in line with the median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Tempest Therapeutics (TPST)$7.64MN/AN/A0.0%-783.6%0.0%0.00%
    Marker Therapeutics Inc (MRKR)$14.51MN/A14.5x-245.5%N/A-51.0%0.00%
    GT Biopharma Inc (GTBP)$7.67MN/AN/A0.0%N/A0.0%0.00%
    Intensity Therapeutics, Inc. Common stock (INTS)$10.17MN/AN/A0.0%N/A0.0%0.00%
    CytoMed Therapeutics Limited Ordinary Shares (GDTC)$9.90MN/A16.4x0.0%-72.3%-15.9%0.00%
    Theriva Biologics Inc. (TOVX)$6.61MN/A21.5x0.0%-52.3%0.0%0.00%
    Tscan Therapeutics Inc (TCRX)$10.89MN/A3.6x0.0%-129.7%-65.8%0.00%
    Moleculin Biotech Inc (MBRX)$8.02MN/AN/A0.0%N/A0.0%0.00%
    Processa Pharmaceuticals Inc (PCSA)$5.20MN/AN/A0.0%N/A0.0%0.00%
    Aprea Therapeutics Inc (APRE)$5.91MN/AN/A0.0%N/A-98.4%0.00%
    VistaGen Therapeutics Inc (VTGN)$8.01MN/A3.4x0.0%N/A-46.5%0.00%
    Lantern Pharma Inc (LTRN)$6.47MN/AN/A0.0%N/A0.0%0.00%
    In8bio Inc (INAB)$8.86MN/AN/A0.0%N/A0.0%0.00%
    Peer median$8.02MN/A14.5x0.0%-72.3%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Tempest Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Marker Therapeutics Inc (MRKR)
    Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based...
    MRKR competitors
    GT Biopharma Inc (GTBP)
    GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its...
    GTBP competitors
    Intensity Therapeutics, Inc. Common stock (INTS)
    Intensity Therapeutics, Inc. is a pioneering biotechnology firm committed to revolutionizing cancer treatment through cutting-edge drug delivery systems.
    INTS competitors
    CytoMed Therapeutics Limited Ordinary Shares (GDTC)
    CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human...
    Theriva Biologics Inc. (TOVX)
    Theriva Biologics Inc., a clinical-stage company, develops therapies to treat diseases in areas of high unmet need.
    TOVX competitors
    Tscan Therapeutics Inc (TCRX)
    Tscan Therapeutics Inc (TCRX) is a pioneering clinical-stage biotechnology company specializing in precision oncology through its proprietary T cell receptor...
    TCRX competitors
    Moleculin Biotech Inc (MBRX)
    Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant...
    MBRX competitors
    Processa Pharmaceuticals Inc (PCSA)
    Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of patients...
    PCSA competitors
    Aprea Therapeutics Inc (APRE)
    Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies that reactivate the mutant p53 tumor suppressor...
    APRE competitors
    VistaGen Therapeutics Inc (VTGN)
    VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing and commercializing several drugs with the potential...
    VTGN competitors
    Lantern Pharma Inc (LTRN)
    Lantern Pharma Inc., a clinical-stage biotechnology company, focuses on developing precision cancer therapies using artificial intelligence, genomics...
    LTRN competitors
    In8bio Inc (INAB)
    IN8bio, Inc., a clinical-stage biotechnology company, is focused on developing new therapies for the treatment of cancers...
    INAB competitors

    Frequently Asked Questions About TPST

    Who are Tempest Therapeutics' main competitors?

    The companies most similar to Tempest Therapeutics include Marker Therapeutics (MRKR), GT Biopharma (GTBP), Intensity Therapeutics, Inc. Common stock (INTS), CytoMed Therapeutics Limited Ordinary Shares (GDTC) and Theriva Biologics (TOVX), listed from the closest match.

    Who is Tempest Therapeutics' biggest competitor?

    Marker Therapeutics (MRKR) is both the largest of the similar companies at $14.51M and the closest match by business profile, size, sector and industry.

    How does TPST stock compare with its competitors?

    TPST's net margin is 0.0% against a peer median of 0.0%.

    Which of Tempest Therapeutics' competitors pays a higher dividend?

    Tempest Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Tempest Therapeutics bigger than its competitors?

    No. Tempest Therapeutics is 9th by market cap among the 13 companies on this page; the largest is Marker Therapeutics (MRKR) at $14.51M.